Stem definition | Drug id | CAS RN |
---|---|---|
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics | 947 | 51-61-6 |
Dose | Unit | Route |
---|---|---|
0.50 | g | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 470 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 0.74 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 65.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.87 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.42 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 1974 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Renal injury | 166.07 | 23.88 | 59 | 6479 | 9482 | 46670042 |
Hypotension | 155.08 | 23.88 | 176 | 6362 | 232413 | 46447111 |
Multiple organ dysfunction syndrome | 144.57 | 23.88 | 90 | 6448 | 51620 | 46627904 |
Fear | 135.86 | 23.88 | 59 | 6479 | 16113 | 46663411 |
Renal failure | 133.15 | 23.88 | 117 | 6421 | 113477 | 46566047 |
Cardiac arrest | 117.85 | 23.88 | 99 | 6439 | 90300 | 46589224 |
Renal impairment | 117.17 | 23.88 | 91 | 6447 | 74281 | 46605243 |
Injury | 116.42 | 23.88 | 74 | 6464 | 43953 | 46635571 |
Anhedonia | 114.71 | 23.88 | 46 | 6492 | 10289 | 46669235 |
Unevaluable event | 94.06 | 23.88 | 66 | 6472 | 46109 | 46633415 |
Emotional distress | 89.67 | 23.88 | 55 | 6483 | 30652 | 46648872 |
Cardiogenic shock | 85.44 | 23.88 | 43 | 6495 | 16341 | 46663183 |
Shock | 73.83 | 23.88 | 43 | 6495 | 21802 | 46657722 |
Diabetes insipidus | 68.25 | 23.88 | 21 | 6517 | 2153 | 46677371 |
Renal ischaemia | 62.80 | 23.88 | 15 | 6523 | 588 | 46678936 |
Bradycardia | 55.90 | 23.88 | 57 | 6481 | 66241 | 46613283 |
Blood pressure decreased | 53.46 | 23.88 | 52 | 6486 | 57107 | 46622417 |
PCO2 increased | 51.91 | 23.88 | 15 | 6523 | 1239 | 46678285 |
Blood bicarbonate decreased | 50.77 | 23.88 | 18 | 6520 | 2867 | 46676657 |
Blood pH decreased | 48.55 | 23.88 | 17 | 6521 | 2610 | 46676914 |
Oxygen saturation abnormal | 47.99 | 23.88 | 17 | 6521 | 2701 | 46676823 |
PO2 increased | 47.55 | 23.88 | 13 | 6525 | 877 | 46678647 |
Acute kidney injury | 43.04 | 23.88 | 99 | 6439 | 235756 | 46443768 |
Metabolic acidosis | 41.44 | 23.88 | 38 | 6500 | 38742 | 46640782 |
Fatigue | 41.19 | 23.88 | 17 | 6521 | 608680 | 46070844 |
Stress | 41.05 | 23.88 | 43 | 6495 | 51508 | 46628016 |
Ventricular tachycardia | 41.04 | 23.88 | 27 | 6511 | 16940 | 46662584 |
Septic shock | 36.94 | 23.88 | 43 | 6495 | 57850 | 46621674 |
Cardiac failure | 34.64 | 23.88 | 49 | 6489 | 79899 | 46599625 |
Haemodynamic instability | 33.72 | 23.88 | 18 | 6520 | 7707 | 46671817 |
Status epilepticus | 33.21 | 23.88 | 22 | 6516 | 13957 | 46665567 |
Activated partial thromboplastin time prolonged | 32.76 | 23.88 | 17 | 6521 | 6872 | 46672652 |
Platelet count decreased | 31.65 | 23.88 | 53 | 6485 | 99971 | 46579553 |
Disseminated intravascular coagulation | 31.48 | 23.88 | 24 | 6514 | 18981 | 46660543 |
Pulmonary haemorrhage | 30.78 | 23.88 | 16 | 6522 | 6489 | 46673035 |
Arthralgia | 30.30 | 23.88 | 7 | 6531 | 364596 | 46314928 |
Electroencephalogram abnormal | 29.24 | 23.88 | 13 | 6525 | 3741 | 46675783 |
Sepsis | 29.18 | 23.88 | 61 | 6477 | 135953 | 46543571 |
Left ventricular dysfunction | 28.97 | 23.88 | 18 | 6520 | 10237 | 46669287 |
Foetal death | 28.97 | 23.88 | 17 | 6521 | 8726 | 46670798 |
Anxiety | 28.44 | 23.88 | 72 | 6466 | 181885 | 46497639 |
Clonus | 28.20 | 23.88 | 13 | 6525 | 4067 | 46675457 |
Intraventricular haemorrhage neonatal | 27.68 | 23.88 | 6 | 6532 | 151 | 46679373 |
Blood urea increased | 27.38 | 23.88 | 25 | 6513 | 25327 | 46654197 |
Enzyme induction | 26.95 | 23.88 | 5 | 6533 | 55 | 46679469 |
Hepatic failure | 26.81 | 23.88 | 28 | 6510 | 33388 | 46646136 |
Malaise | 26.27 | 23.88 | 7 | 6531 | 331225 | 46348299 |
Respiratory failure | 25.78 | 23.88 | 47 | 6491 | 94769 | 46584755 |
Anuria | 24.79 | 23.88 | 17 | 6521 | 11414 | 46668110 |
Headache | 24.23 | 23.88 | 19 | 6519 | 478333 | 46201191 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fear | 225.20 | 19.01 | 91 | 8005 | 10734 | 29933648 |
Renal injury | 191.56 | 19.01 | 83 | 8013 | 11646 | 29932736 |
Injury | 189.89 | 19.01 | 100 | 7996 | 21631 | 29922751 |
Multiple organ dysfunction syndrome | 184.78 | 19.01 | 146 | 7950 | 63341 | 29881041 |
Anhedonia | 162.55 | 19.01 | 67 | 8029 | 8302 | 29936080 |
Unevaluable event | 147.20 | 19.01 | 97 | 7999 | 31688 | 29912694 |
Renal failure | 133.76 | 19.01 | 169 | 7927 | 128797 | 29815585 |
Emotional distress | 116.60 | 19.01 | 65 | 8031 | 15700 | 29928682 |
Stress | 109.10 | 19.01 | 68 | 8028 | 20167 | 29924215 |
Renal impairment | 83.40 | 19.01 | 108 | 7988 | 84076 | 29860306 |
Hypotension | 79.34 | 19.01 | 170 | 7926 | 200395 | 29743987 |
Cardiogenic shock | 67.34 | 19.01 | 47 | 8049 | 16814 | 29927568 |
Anxiety | 64.73 | 19.01 | 99 | 7997 | 89772 | 29854610 |
Shock | 56.69 | 19.01 | 48 | 8048 | 22811 | 29921571 |
Disseminated intravascular coagulation | 51.81 | 19.01 | 45 | 8051 | 22126 | 29922256 |
Blood pressure decreased | 50.66 | 19.01 | 63 | 8033 | 47012 | 29897370 |
Ventricular fibrillation | 48.63 | 19.01 | 37 | 8059 | 15101 | 29929281 |
Hypertrophic cardiomyopathy | 46.55 | 19.01 | 15 | 8081 | 918 | 29943464 |
Blood urea increased | 43.77 | 19.01 | 48 | 8048 | 31333 | 29913049 |
Neonatal disorder | 42.60 | 19.01 | 14 | 8082 | 912 | 29943470 |
Incision site pain | 42.15 | 19.01 | 17 | 8079 | 1987 | 29942395 |
Cardiac arrest | 40.38 | 19.01 | 82 | 8014 | 92768 | 29851614 |
Ventricular tachycardia | 39.51 | 19.01 | 40 | 8056 | 23822 | 29920560 |
Distributive shock | 38.95 | 19.01 | 12 | 8084 | 634 | 29943748 |
Torsade de pointes | 38.30 | 19.01 | 24 | 8072 | 7166 | 29937216 |
Fatigue | 37.62 | 19.01 | 20 | 8076 | 320653 | 29623729 |
Pain | 36.60 | 19.01 | 116 | 7980 | 172525 | 29771857 |
Lymphocyte count decreased | 35.37 | 19.01 | 34 | 8062 | 19021 | 29925361 |
Pulmonary haemorrhage | 34.75 | 19.01 | 25 | 8071 | 9367 | 29935015 |
Metabolic acidosis | 32.32 | 19.01 | 45 | 8051 | 37416 | 29906966 |
Dizziness | 31.68 | 19.01 | 7 | 8089 | 194902 | 29749480 |
Septic shock | 31.05 | 19.01 | 59 | 8037 | 63548 | 29880834 |
Urine output decreased | 29.53 | 19.01 | 23 | 8073 | 9706 | 29934676 |
Headache | 28.73 | 19.01 | 7 | 8089 | 182299 | 29762083 |
Neutrophil count increased | 27.79 | 19.01 | 27 | 8069 | 15296 | 29929086 |
Arthralgia | 26.26 | 19.01 | 3 | 8093 | 135788 | 29808594 |
Respiratory failure | 25.41 | 19.01 | 72 | 8024 | 100570 | 29843812 |
Anuria | 24.21 | 19.01 | 21 | 8075 | 10295 | 29934087 |
Asthenia | 24.19 | 19.01 | 15 | 8081 | 221275 | 29723107 |
Bradycardia | 23.99 | 19.01 | 54 | 8042 | 65472 | 29878910 |
Cardiac failure | 23.36 | 19.01 | 62 | 8034 | 83356 | 29861026 |
Acidosis | 22.24 | 19.01 | 20 | 8076 | 10281 | 29934101 |
Intraventricular haemorrhage neonatal | 22.02 | 19.01 | 6 | 8090 | 204 | 29944178 |
Nausea | 21.91 | 19.01 | 29 | 8067 | 296928 | 29647454 |
Red blood cells urine positive | 21.75 | 19.01 | 10 | 8086 | 1607 | 29942775 |
Oliguria | 21.32 | 19.01 | 17 | 8079 | 7422 | 29936960 |
Sepsis | 21.25 | 19.01 | 87 | 8009 | 146308 | 29798074 |
Toxic epidermal necrolysis | 20.88 | 19.01 | 25 | 8071 | 17915 | 29926467 |
Left ventricle outflow tract obstruction | 19.49 | 19.01 | 5 | 8091 | 134 | 29944248 |
Source | Code | Description |
---|---|---|
ATC | C01CA04 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
FDA CS | M0003647 | Catecholamines |
FDA EPC | N0000175570 | Catecholamine |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35522 | beta-adrenergic receptor agonist |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
CHEBI has role | CHEBI:48560 | dopamine agents |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:76971 | e.coli metabolites |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Low cardiac output syndrome | indication | 44088000 | |
Low blood pressure | indication | 45007003 | |
Decompensated cardiac failure | indication | 195111005 | |
Sinus bradycardia | off-label use | 49710005 | |
Acute nephropathy | off-label use | 58574008 | |
Tachyarrhythmia | contraindication | 6285003 | |
Hypovolemia | contraindication | 28560003 | |
Ventricular arrhythmia | contraindication | 44103008 | |
Acidosis | contraindication | 51387008 | |
Pheochromocytoma | contraindication | 302835009 | |
Hypoxia | contraindication | 389086002 | |
Occlusive Vascular Disease | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.96 | acidic |
pKa2 | 12.98 | acidic |
pKa3 | 10.61 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | AGONIST | Ki | 5 | WOMBAT-PK | CHEMBL | |||
D(1B) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Beta-2 adrenergic receptor | GPCR | Kd | 4.19 | CHEMBL | |||||
Melatonin receptor type 1A | GPCR | Ki | 5.15 | CHEMBL | |||||
Melatonin receptor type 1B | GPCR | Ki | 5.04 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.19 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.08 | PDSP | |||||
D(3) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
D(2) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
D(1A) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Sodium-dependent noradrenaline transporter | Transporter | IC50 | 8.18 | WOMBAT-PK | |||||
Trace amine-associated receptor 1 | GPCR | Ki | 6.37 | WOMBAT-PK | |||||
Dopamine beta-hydroxylase | Enzyme | Km | 3 | WOMBAT-PK | |||||
FAD-linked sulfhydryl oxidase ALR | Enzyme | AC50 | 5.85 | CHEMBL | |||||
Lysine-specific demethylase 4E | Enzyme | IC50 | 5.52 | CHEMBL | |||||
D(4) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Dopamine receptor | GPCR | IC50 | 8.43 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 6.70 | CHEMBL | |||||
Adenylate cyclase | Enzyme | EC50 | 5.46 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 8.15 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 5 | CHEMBL | |||||
D(4) dopamine receptor | GPCR | EC50 | 8.62 | CHEMBL | |||||
Dopamine receptor | GPCR | IC50 | 5.27 | CHEMBL | |||||
Adrenergic receptor alpha-2 | GPCR | Ki | 7.24 | CHEMBL | |||||
Adrenergic receptor alpha-1 | GPCR | Ki | 4.85 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 8.74 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | Ki | 4.30 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 6.82 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 8.35 | CHEMBL | |||||
D(3) dopamine receptor | GPCR | Ki | 7.96 | CHEMBL | |||||
Opioid receptor | GPCR | IC50 | 5.52 | CHEMBL | |||||
Adenosine A2b receptor | GPCR | Ki | 6.01 | CHEMBL | |||||
M18 aspartyl aminopeptidase | Unclassified | IC50 | 5.70 | CHEMBL |
ID | Source |
---|---|
4019733 | VUID |
N0000147825 | NUI |
D00633 | KEGG_DRUG |
62-31-7 | SECONDARY_CAS_RN |
4018656 | VANDF |
4019733 | VANDF |
C0013030 | UMLSCUI |
CHEBI:18243 | CHEBI |
LDP | PDB_CHEM_ID |
CHEMBL59 | ChEMBL_ID |
CHEMBL1557 | ChEMBL_ID |
DB00988 | DRUGBANK_ID |
D004298 | MESH_DESCRIPTOR_UI |
681 | PUBCHEM_CID |
940 | IUPHAR_LIGAND_ID |
2417 | INN_ID |
VTD58H1Z2X | UNII |
3628 | RXNORM |
3090 | MMSL |
4632 | MMSL |
6641 | MMSL |
d00216 | MMSL |
001787 | NDDF |
004721 | NDDF |
16257000 | SNOMEDCT_US |
412383006 | SNOMEDCT_US |
59187003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9252 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9253 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9254 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9255 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
MYOCARD-DX | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-1840 | INJECTION | 80 mg | INTRAVENOUS | EXPORT ONLY | 20 sections |
MYOCARD-DX | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-1880 | INJECTION | 800 mg | INTRAVENOUS | EXPORT ONLY | 20 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1005 | INJECTION, SOLUTION | 80 mg | INTRAVENOUS | NDA | 22 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1007 | INJECTION, SOLUTION | 160 mg | INTRAVENOUS | NDA | 22 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1009 | INJECTION, SOLUTION | 320 mg | INTRAVENOUS | NDA | 22 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-5820 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |
Dopamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7808 | INJECTION, SOLUTION | 0.80 mg | INTRAVENOUS | NDA | 25 sections |
Dopamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7809 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 25 sections |
Dopamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7810 | INJECTION, SOLUTION | 3.20 mg | INTRAVENOUS | NDA | 25 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9104 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |
DOPAMINE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1220 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 12 sections |
DOPAMINE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1291 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 12 sections |
DOPAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1316 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 13 sections |
DOPAMINE HCI IN 5% DEXTROSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1458 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 13 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-104 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-820 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7066 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |